Yale Bulletin and Calendar

January 18, 2002Volume 30, Number 15Two-Week Issue



BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

YALE SCOREBOARD

CLASSIFIED ADS


SEARCH ARCHIVES

DEADLINES

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Tamborlane to head national
project on juvenile diabetes

A Yale expert on juvenile diabetes is heading a national group that will test the most advanced blood sugar sensing technology for children with Type 1 diabetes -- research that investigtors hope may lead to the first artificial pancreas.

Dr. William Tamborlane of the School of Medicine will lead the project, which involves five centers around the country and is sponsored by the National Institute of Child Health and Human Development. In addition to Yale, the centers are at the University of Colorado, Stanford University, the University of Iowa and a diabetes center in Jacksonville, Florida.

"The research relates to advances we have seen in the last couple of years in glucose sensor systems," says Tamborlane, who is professor and section chief of pediatric endocrinology. "Over the last 20 years we have tried to regulate diabetes by having patients prick their fingers four times a day and measure glucose levels. Now there are two U.S. Food and Drug Administration-approved continuous glucose monitoring devices available."

Tamborlane says all the participating institutions were already involved in research on Type 1 diabetes, which is a more severe form of diabetes that affects children. Type 2 diabetes generally is diagnosed in adults.

"The NIH felt it would be important to put together a group of leading centers in the country to study, in a scientifically rigorous and unbiased way, how these glucose monitoring systems could be used in children with Type 1 diabetes," says Tamborlane, principal investigator for the Yale study and chair of the group's steering committee.

Diabetes remains an extremely difficult disease to manage, particularly in young patients, notes the Yale physician. Although physicians have succeeded in lowering blood sugar levels, the continuing major obstacle is the increased frequency of severe hypoglycemic reactions that lead to seizures and coma, he explains.

"Sensor technology could be a major breakthrough to better adjust our therapy to reduce some of the risk of treatment," he says. "If the sensors work reliably over six months to a year, then, with continuous subcutaneous insulin infusion therapy, this could be an important first step in the development of an artificial pancreas."

The first study the centers will undertake is validating the accuracy of the two available glucose sensors and how they work under varying conditions, such as during exercise or after eating different meals.


T H I SW E E K ' SS T O R I E S

Yale and Unions agree to seek more effective negotiations process

Campus events honor legacy of Martin Luther King Jr.

Center receives over $12 million in grants for research on AIDS

IN FOCUS: Electrical Engineering

'Painted Ladies' of king's court featured in exhibition


MEDICAL SCHOOL NEWS

'Art for All Seasons' showcases works by Asian artists

Works depict the human form, both draped and undraped

'A Streetcar Named Desire' comes to the Yale stage

Petrarch's poetry will be highlighted in a campus talk . . .

Symposium to examine roots of modern visual culture

Woodcut offers panoramic view of 16th-century Muslim life


OBITUARIES

Funny things will happen during a Roman-style comedy week

Standing, Special and Appointments Committees

Yale seeks nominees for 2001 Seton Elm-Ivy Awards

Fellowships for foreign study and travel offered by YCIAS

Yale Books in Brief

Campus Notes



Bulletin Home|Visiting on Campus|Calendar of Events|In the News|Bulletin Board

Yale Scoreboard|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs Home|News Releases| E-Mail Us|Yale Home Page